Progyny (NASDAQ:PGNY – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Truist Financial in a report issued on Tuesday, Benzinga reports. They presently have a $42.00 target price on the stock, up from their previous target price of $36.00. Truist Financial‘s price target would indicate a potential upside of 14.53% from the stock’s previous close.
Other equities research analysts have also issued research reports about the stock. Citizens Jmp raised their target price on shares of Progyny from $33.00 to $38.00 and gave the stock a “market outperform” rating in a report on Thursday, November 5th. Cantor Fitzgerald raised their price objective on shares of Progyny from $31.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, November 5th. Weiss Ratings upgraded Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Jefferies Financial Group set a $33.00 target price on Progyny in a research note on Tuesday, September 8th. Finally, BTIG Research boosted their target price on shares of Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Eleven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $35.83.
View Our Latest Report on Progyny
Progyny Price Performance
Shares of PGNY opened at $36.67 on Tuesday. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of 33.86, a price-to-earnings-growth ratio of 1.70 and a beta of 0.97. Progyny has a 1 year low of $16.10 and a 1 year high of $37.20. The business’s 50 day simple moving average is $28.70 and its 200-day simple moving average is $24.94.
Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The company had revenue of $341.25 million for the quarter, compared to the consensus estimate of $340.76 million. During the same quarter in the prior year, the firm earned $0.15 earnings per share. Progyny’s revenue was up 8.9% on a year-over-year basis. On average, sell-side analysts expect that Progyny will post 1.43 earnings per share for the current year.
Insider Buying and Selling at Progyny
In other Progyny news, CEO Peter Anevski sold 236,630 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $35.84, for a total transaction of $8,480,819.20. Following the transaction, the chief executive officer owned 710,972 shares of the company’s stock, valued at approximately $25,481,236.48. This trade represents a 24.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark S. Livingston sold 2,139 shares of the business’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $30.00, for a total value of $64,170.00. Following the completion of the transaction, the chief financial officer directly owned 70,314 shares of the company’s stock, valued at approximately $2,109,420. The trade was a 2.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 630,072 shares of company stock worth $22,363,084. Insiders own 9.90% of the company’s stock.
Institutional Investors Weigh In On Progyny
A number of hedge funds and other institutional investors have recently bought and sold shares of PGNY. Aristides Capital LLC acquired a new stake in Progyny in the third quarter worth about $346,000. Goldman Sachs Group Inc. boosted its position in Progyny by 23.3% in the third quarter. Goldman Sachs Group Inc. now owns 530,279 shares of the company’s stock valued at $13,358,000 after buying an additional 100,335 shares during the last quarter. AWM Investment Company Inc. lifted its stake in Progyny by 6.8% during the 3rd quarter. AWM Investment Company Inc. now owns 235,000 shares of the company’s stock valued at $5,920,000 after acquiring an additional 15,000 shares during the period. Kovack Advisors Inc. acquired a new stake in shares of Progyny in the third quarter worth $72,000. Finally, First Trust Advisors LP lifted its position in Progyny by 302.2% during the third quarter. First Trust Advisors LP now owns 425,903 shares of the company’s stock valued at $10,728,000 after purchasing an additional 320,010 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.
Progyny Company Profile
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
Further Reading
- Five stocks we like better than Progyny
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
